Skip to main content
Premium Trial:

Request an Annual Quote

Icoria Sells Ag Business to Monsanto for $6.8M, Re-emerges as Biomarker-Discovery Shop

NEW YORK, March 24 (GenomeWeb News) - Icoria has sold its agricultural genomics assets to Monsanto for $6.75 million, existing the ag-genomics business and refashioning itself as a biomarker-discovery company, the firm said today.

 

Monsanto, which will get Icoria's Research Triangle Park, NC, facility in the deal, paid $4.75 million up front for the assets, with the remainder to be paid in January 2006, Icoria said.

 

Icoria, formerly known as Paradigm Genetics, said it expects to reduce its headcount by 70 staffers by the end of the second quarter, bringing headcount to 120. It added that 60 of these employees are expected to join Monsanto. Additional lay-offs occured at Icoria's Pittsburghoffices, the company said.

 

Icoria has conducted genomic agricultural research under contract for Monsanto, Pioneer Hi-Bred, and DuPont Crop Science, and said it will exit the field after concluding its contracts. No date was provided. 

 

"Monsanto has more resources to fund and develop the GeneFunction Factory platform in transgenic plant applications than Icoria could hope to provide," Heinrich Gugger, president and CEO of Icoria, said in a statement. Gugger joined the company in July 2003, leaving his position as president of the North American crop-protection business for Syngenta.

 

Icoria said it expects savings of $5.2 million from reduced lease obligations, $3 million in net cash flow benefit, as well as an additional $4 million in annual savings in general and administrative costs.

 

With the sale of these assets, Icoria, which  changed its name from Paradigm Genetics last August, said it would reposition itself to focus on biomarker discovery for diabetes, obesity, and liver injury, using its metabolomics, gene-expression profiling, tissue analysis software, and computational assets.

 

The company will continue to offer its services as a research partner to pharma and biotech companies, and will maintain its Paradigm Array Labs business, which provides gene-expression profiling services using Affymetrix, Agilent, and proprietary technologies.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.